International Stem Cell Corp (ISCO) VP Sophia Garnette Sells 10,636 Shares of Stock

International Stem Cell Corp (OTCMKTS:ISCO) VP Sophia Garnette sold 10,636 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $1.54, for a total value of $16,379.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Sophia Garnette also recently made the following trade(s):

  • On Tuesday, October 2nd, Sophia Garnette sold 1,494 shares of International Stem Cell stock. The shares were sold at an average price of $1.58, for a total value of $2,360.52.

International Stem Cell stock traded up $0.05 during midday trading on Friday, reaching $1.60. The stock had a trading volume of 611 shares, compared to its average volume of 7,583. International Stem Cell Corp has a twelve month low of $1.25 and a twelve month high of $1.77. The stock has a market capitalization of $10.73 million, a P/E ratio of -1.09 and a beta of -0.24.

International Stem Cell (OTCMKTS:ISCO) last issued its earnings results on Thursday, November 15th. The biotechnology company reported ($0.10) earnings per share for the quarter. International Stem Cell had a negative net margin of 23.26% and a negative return on equity of 123.16%. The firm had revenue of $3.20 million during the quarter. As a group, analysts predict that International Stem Cell Corp will post -0.32 EPS for the current fiscal year.

Separately, Zacks Investment Research upgraded International Stem Cell from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a report on Wednesday, August 22nd.

TRADEMARK VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at

International Stem Cell Company Profile

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes.

See Also: Float

Insider Buying and Selling by Quarter for International Stem Cell (OTCMKTS:ISCO)

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with's FREE daily email newsletter.

Leave a Reply